<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322500</url>
  </required_header>
  <id_info>
    <org_study_id>07/2019</org_study_id>
    <nct_id>NCT04322500</nct_id>
  </id_info>
  <brief_title>Probiotics for Chalaziosis Treatment in Children</brief_title>
  <official_title>Intestinal Microbiota: a New Target for Chalaziosis Treatment in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Molise</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Molise</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is growing evidence encouraging the use of probiotics in many conditions in children.
      The aim of the investigator's study is to define the possible beneficial impact of probiotics
      on paediatric patients affected by chalaziosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective comparative pilot study on 26 children suffering from chalaziosis. They will be
      randomly divided in two groups. One group will receive conservative treatment and the other
      one will receive conservative treatment and a daily supplementation of probiotics. All
      patients will be evaluated at 2-week intervals for 3 months. If the lesion will not disappear
      or decrease in size to 1 mm or less in diameter on subsequent visits, the same procedure will
      be repeated for another 3-months cycle. The follow up periods extend from 3 to 6 months
      according to the results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective comparative pilot study with two groups randomly divided</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Taken for a Complete Resolution of the Chalaziosis</measure>
    <time_frame>3 months</time_frame>
    <description>change in the time taken for complete resolution of chalaziosis (complete disappearance of the eyelid mass lesions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Recurrences</measure>
    <time_frame>3 months</time_frame>
    <description>complete ophthalmological evaluation was done weekly during the first month and then monthly in order to evaluate possible recurrences (presence of a new eyelid mass lesion)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Chalazion</condition>
  <arm_group>
    <arm_group_label>Group A: conservative</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>conservative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis</description>
    <arm_group_label>Group B: probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conservative treatment</intervention_name>
    <description>lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
    <arm_group_label>Group A: conservative</arm_group_label>
    <arm_group_label>Group B: probiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  paediatric patients

          -  presence of one or more eyelid mass lesions (history of rapid onset of painful
             inflamed mass that had reached a stationary size for more than 2 months)

        Exclusion Criteria:

          -  eyelid infection

          -  chalazion duration &lt; 1 month

          -  nonpalpable chalazion

          -  suspicion of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Costagliola, Full Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Molise</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Molise</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://fao.org/3/a-a0512e.pdf</url>
    <description>probiotics definition</description>
  </link>
  <link>
    <url>http://ecronicon.com/ecop/pdf/ECOP-03-000078.pdf</url>
    <description>Infective and Inflammatory Eyelid Disorders: Conventional and Unconventional Therapies to Maintain Eye Health and Avoid Lid Surgery</description>
  </link>
  <reference>
    <citation>George Kerry R, Patra JK, Gouda S, Park Y, Shin HS, Das G. Benefaction of probiotics for human health: A review. J Food Drug Anal. 2018 Jul;26(3):927-939. doi: 10.1016/j.jfda.2018.01.002. Epub 2018 Feb 2. Review.</citation>
    <PMID>29976412</PMID>
  </reference>
  <reference>
    <citation>McLean MH, Dieguez D Jr, Miller LM, Young HA. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 2015 Feb;64(2):332-41. doi: 10.1136/gutjnl-2014-308514. Epub 2014 Nov 21. Review.</citation>
    <PMID>25416067</PMID>
  </reference>
  <reference>
    <citation>Scher JU, Littman DR, Abramson SB. Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis Rheumatol. 2016 Jan;68(1):35-45. doi: 10.1002/art.39259. Review.</citation>
    <PMID>26331579</PMID>
  </reference>
  <reference>
    <citation>Ochoa-Rep√°raz J, Kasper LH. The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. Transl Res. 2017 Jan;179:126-138. doi: 10.1016/j.trsl.2016.07.016. Epub 2016 Jul 28. Review.</citation>
    <PMID>27519147</PMID>
  </reference>
  <reference>
    <citation>Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, Ali MH, Sharma S, Tyagi M, Shivaji S. Dysbiosis in the Gut Bacterial Microbiome of Patients with Uveitis, an Inflammatory Disease of the Eye. Indian J Microbiol. 2018 Dec;58(4):457-469. doi: 10.1007/s12088-018-0746-9. Epub 2018 Jun 4.</citation>
    <PMID>30262956</PMID>
  </reference>
  <reference>
    <citation>Iovieno A, Lambiase A, Sacchetti M, Stampachiacchiere B, Micera A, Bonini S. Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):435-41. Epub 2007 Nov 27.</citation>
    <PMID>18040708</PMID>
  </reference>
  <reference>
    <citation>Tavakoli A, Flanagan JL. The Case for a More Holistic Approach to Dry Eye Disease: Is It Time to Move beyond Antibiotics? Antibiotics (Basel). 2019 Jun 30;8(3). pii: E88. doi: 10.3390/antibiotics8030088. Review.</citation>
    <PMID>31262073</PMID>
  </reference>
  <reference>
    <citation>Lin P. The role of the intestinal microbiome in ocular inflammatory disease. Curr Opin Ophthalmol. 2018 May;29(3):261-266. doi: 10.1097/ICU.0000000000000465. Review.</citation>
    <PMID>29538183</PMID>
  </reference>
  <reference>
    <citation>Baim AD, Movahedan A, Farooq AV, Skondra D. The microbiome and ophthalmic disease. Exp Biol Med (Maywood). 2019 Apr;244(6):419-429. doi: 10.1177/1535370218813616. Epub 2018 Nov 21. Review.</citation>
    <PMID>30463439</PMID>
  </reference>
  <reference>
    <citation>Kugadas A, Gadjeva M. Impact of Microbiome on Ocular Health. Ocul Surf. 2016 Jul;14(3):342-9. doi: 10.1016/j.jtos.2016.04.004. Epub 2016 May 14. Review.</citation>
    <PMID>27189865</PMID>
  </reference>
  <reference>
    <citation>Lin P. Importance of the intestinal microbiota in ocular inflammatory diseases: A review. Clin Exp Ophthalmol. 2019 Apr;47(3):418-422. doi: 10.1111/ceo.13493. Epub 2019 Mar 25. Review.</citation>
    <PMID>30834680</PMID>
  </reference>
  <reference>
    <citation>Sansotta N, Peroni DG, Romano S, Rugiano A, Vuilleumier P, Baviera G; Italian Society of Pediatric Allergy, Immunology (SIAIP), Microbiota Committee, Italy. The good bugs: the use of probiotics in pediatrics. Curr Opin Pediatr. 2019 Oct;31(5):661-669. doi: 10.1097/MOP.0000000000000808. Review.</citation>
    <PMID>31356353</PMID>
  </reference>
  <reference>
    <citation>Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol. 2019 May 14;19(1):110. doi: 10.1186/s12886-019-1118-x.</citation>
    <PMID>31088416</PMID>
  </reference>
  <reference>
    <citation>Malekahmadi M, Farrahi F, Tajdini A. Serum Vitamin A Levels in Patients with Chalazion. Med Hypothesis Discov Innov Ophthalmol. 2017 Fall;6(3):63-66.</citation>
    <PMID>29392144</PMID>
  </reference>
  <reference>
    <citation>Yam JC, Tang BS, Chan TM, Cheng AC. Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol. 2014 Mar-Apr;24(2):159-63. doi: 10.5301/ejo.5000341. Epub 2013 Jul 16.</citation>
    <PMID>23873491</PMID>
  </reference>
  <reference>
    <citation>Lu LJ, Liu J. Human Microbiota and Ophthalmic Disease. Yale J Biol Med. 2016 Sep 30;89(3):325-330. eCollection 2016 Sep. Review.</citation>
    <PMID>27698616</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <results_first_submitted>April 2, 2020</results_first_submitted>
  <results_first_submitted_qc>April 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Molise</investigator_affiliation>
    <investigator_full_name>Ciro Costagliola</investigator_full_name>
    <investigator_title>Full Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>microbiome/microbiota</keyword>
  <keyword>probiotics</keyword>
  <keyword>chalaziosis</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04322500/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A: Conservative</title>
          <description>conservative treatment
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
        <group group_id="P2">
          <title>Group B: Probiotics</title>
          <description>in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01)
probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Conservative</title>
          <description>conservative treatment
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
        <group group_id="B2">
          <title>Group B: Probiotics</title>
          <description>in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01)
probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.2"/>
                    <measurement group_id="B2" value="8.6" spread="1.9"/>
                    <measurement group_id="B3" value="8.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Taken for a Complete Resolution of the Chalaziosis</title>
        <description>change in the time taken for complete resolution of chalaziosis (complete disappearance of the eyelid mass lesions)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Conservative</title>
            <description>conservative treatment
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Probiotics</title>
            <description>in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01)
probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken for a Complete Resolution of the Chalaziosis</title>
          <description>change in the time taken for complete resolution of chalaziosis (complete disappearance of the eyelid mass lesions)</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="12.4"/>
                    <measurement group_id="O2" value="28.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Recurrences</title>
        <description>complete ophthalmological evaluation was done weekly during the first month and then monthly in order to evaluate possible recurrences (presence of a new eyelid mass lesion)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Conservative</title>
            <description>conservative treatment
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Probiotics</title>
            <description>in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01)
probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recurrences</title>
          <description>complete ophthalmological evaluation was done weekly during the first month and then monthly in order to evaluate possible recurrences (presence of a new eyelid mass lesion)</description>
          <units>recurreces</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: Conservative</title>
          <description>conservative treatment
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
        <group group_id="E2">
          <title>Group B: Probiotics</title>
          <description>in addition to the conservative treatment they receive a probiotics mixture (ST10, LLCO2 and LDB01)
probiotics: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
conservative treatment: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Further studies are needed to confirm this first pilot trial (larger cohort, ocular and gut microbiome analysis).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Ciro Costagliola</name_or_title>
      <organization>University of Molise</organization>
      <phone>+39 0874 404861/ 0874 404896</phone>
      <email>ciro.costagliola@unimol.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

